In addition to the therapeutic potential of modulating the IGF-1-HIF-1α pathway, plasma levels of IGF-1 and IGFBP3 may represent molecular risk indicators for the development of white matter injury in SCD patients. The gene discussed is IGFBP3; the disease is Schnyder corneal dystrophy.